Novel DNA-based therapy achieves reduction in mortality in resistant ovarian cancer

January 15, 2026 Novel DNA-based therapy achieves reduction in mortality in resistant ovarian cancer This article was originally published in Digital Journal Neurable research scientist Alicia Howell-Munson demonstrates the company's headset, which it says can detect early signs of Alzheimer's disease - Copyright AFP Patrick T. Fallon A newly published paper that shows that a DNA-based therapeutic agent called Elenagen demonstrated favourable results for women facing platinum-resistant ovarian cancer. The research shows that the agent, when combined with chemotherapy, increased overall survival compared with chemotherapy alone. The research showed patients who received Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone. The median overall survival increased from approximately 13 months to over 25 months. This was with women facing platinum-resistant ovarian cancer ( PROC). Researchers evaluated the novel DNA-based therapy, administered in combination with the standard chemotherapy, gemcitabine, in women with PROC and elevated CA-125. Elenagen is a plasmid therapy —a small, circular piece of DNA encoding the protein p62/SQSTM1 — currently being developed by the firm CureLab Oncology, Inc. In the randomized Phase II trial, Elenagen was administered once weekly via a simple intramuscular injection. In the reporting, researchers supplementing the standard of care (chemotherapy) with Elenagen, have significantly extended overall survival for patients with the deadliest form of ovarian cancer. Key findings The randomized Phase II clinical trial indicated: Extended Survival: Women who received Elenagen plus chemotherapy lived significantly longer than those who received chemotherapy alone . Doubled Median Overall Survival: Median overall survival increased from approximately 13 months to over 25 months . Reduced Mortality: The risk of death was reduced by nearly 60% . High Safety Profile: Importantly, the addition of Elenagen did not increase treatment-related toxicity. Long-term Responders: Some patients receiving Elenagen survived several years beyond typical expectations for this clinical setting.

The release as fetched from its publisher. curelaboncology.com ↗